Antigens recognized by autologous antibody in patients with renal-cell carcinoma.

Article Details

Citation
Copy to clipboard

Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ

Antigens recognized by autologous antibody in patients with renal-cell carcinoma.

Int J Cancer. 1999 Nov 12;83(4):456-64.

PubMed ID
10508479 [ View in PubMed
]
Abstract

The screening of cDNA expression libraries derived from human tumors with autologous antibody (SEREX) is a powerful method for defining the structure of tumor antigens recognized by the humoral immune system. Sixty-five distinct antigens (NY-REN-1 to NY-REN-65) reactive with autologous IgG were identified by SEREX analysis of 4 renal cancer patients and were characterized in terms of cDNA sequence, mRNA expression pattern, and reactivity with allogeneic sera. REN-9, -10, -19, and -26 have a known association with human cancer. REN-9 (LUCA-15) and REN-10 (gene 21) map to the small cell lung cancer tumor suppressor gene locus on chromosome 3p21.3. REN-19 is equivalent to LKB1/STK11, a gene that is defective in Peutz-Jeghers syndrome and cancer. REN-26 is encoded by the bcr gene involved in the [t(9:22)] bcr/abl translocation. Genes encoding 3 of the antigens in the series showed differential mRNA expression; REN-3 displays a pattern of tissue-specific isoforms, and REN-21 and REN-43 are expressed at a high level in testis in comparison to 15 other normal tissues. The other 62 antigens were broadly expressed in normal tissues. With regard to immunogenicity, 20 of the 65 antigens reacted only with autologous sera. Thirty-three antigens reacted with sera from normal donors, indicating that their immunogenicity is not restricted to cancer. The remaining 12 antigens reacted with sera from 5-25% of the cancer patients but not with sera from normal donors. Seventy percent of the renal cancer patients had antibodies directed against one or more of these 12 antigens. Our results demonstrate the potential of the SEREX approach for the analysis of the humoral immune response against human cancer.

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrialP56181Details
L-lactate dehydrogenase B chainP07195Details
Alanine--tRNA ligase, cytoplasmicP49588Details
L-lactate dehydrogenase A chainP00338Details
Rho-associated protein kinase 1Q13464Details
Heat shock protein HSP 90-alphaP07900Details
Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrialQ9P2R7Details
Nuclear receptor coactivator 1Q15788Details
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoformQ13362Details
Enoyl-CoA delta isomerase 2, mitochondrialO75521Details
Interleukin-1 receptor-associated kinase 4Q9NWZ3Details
Ephrin type-B receptor 2P29323Details
Breakpoint cluster region proteinP11274Details
Stress-induced-phosphoprotein 1P31948Details
Serine/threonine-protein kinase Nek1Q96PY6Details